N van Zandwijk, J G McVie, O Dalesio, A Kirkpatrick
{"title":"EORTC的小细胞肺癌试验。","authors":"N van Zandwijk, J G McVie, O Dalesio, A Kirkpatrick","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>An overview of activities of the EORTC Lung Cancer Coöperative Group in small cell lung cancer is given. Optimal length of therapy, identification of patients with good/bad prognostic factors, role of surgery and the study of new drugs presently are the main areas of interest for the group. With its large patient potential the group is able to verify \"early favourable reports\" and to quickly perform phase II studies.</p>","PeriodicalId":12048,"journal":{"name":"European journal of respiratory diseases. Supplement","volume":"149 ","pages":"57-62"},"PeriodicalIF":0.0000,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Small cell lung cancer trials in the EORTC.\",\"authors\":\"N van Zandwijk, J G McVie, O Dalesio, A Kirkpatrick\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>An overview of activities of the EORTC Lung Cancer Coöperative Group in small cell lung cancer is given. Optimal length of therapy, identification of patients with good/bad prognostic factors, role of surgery and the study of new drugs presently are the main areas of interest for the group. With its large patient potential the group is able to verify \\\"early favourable reports\\\" and to quickly perform phase II studies.</p>\",\"PeriodicalId\":12048,\"journal\":{\"name\":\"European journal of respiratory diseases. Supplement\",\"volume\":\"149 \",\"pages\":\"57-62\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1987-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of respiratory diseases. Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of respiratory diseases. Supplement","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
An overview of activities of the EORTC Lung Cancer Coöperative Group in small cell lung cancer is given. Optimal length of therapy, identification of patients with good/bad prognostic factors, role of surgery and the study of new drugs presently are the main areas of interest for the group. With its large patient potential the group is able to verify "early favourable reports" and to quickly perform phase II studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
